DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/28687340Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/18158338 | https://www.ncbi.nlm.nih.gov/pubmed/28271418 | https://www.ncbi.nlm.nih.gov/pubmed/16380540 | https://www.ncbi.nlm.nih.gov/pubmed/18677709
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28687340
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/18158338 | https://www.ncbi.nlm.nih.gov/pubmed/28271418 | https://www.ncbi.nlm.nih.gov/pubmed/16380540 | https://www.ncbi.nlm.nih.gov/pubmed/18677709
Angiotensin III (Ang III) is a bioactive heptapeptide that is formed from the degradation of the Angiotensin II peptide by aminopeptidase A. In peripheral Angiotensin systems, Angiotensin II is the main effector peptide in the systemic circulation, although exogenous Angiotensin III can be as potent as Angiotensin II in, for example, stimulating aldosterone secretion or inhibiting renin release. In the rat brain, Angiotensin III was found to be equipotent with Angiotensin II as a pressor agent or dipsogen and was bound as avidly to the nervous system as Angiotensin II. Angiotensin receptor subtype AT1 has the greater affinity towards Angiotensin II and is also responsive to Angiotensin III, while the AT2 receptor subtype appears to be more sensitive to Angiotensin III but less responsive to Angiotensin II. Angiotensin III enhances blood pressure, vasopressin release and thirst when it is centrally administrated. Angiotensin III infusion increases blood pressure in healthy volunteers and hypertensive patients as well as augments aldosterone release. Although Angiotensin III does not change renal function in humans, it induces natriuresis in AT, receptor-blocked rats likely by binding to AT2 receptors. In addition, in cultured renal cells, this peptide stimulates the expression of many growth factors, proinflammatory mediators, and extracellular matrix proteins.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL227 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8515427 |
5.57 nM [IC50] | ||
Target ID: CHEMBL4607 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8515427 |
1.74 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16380540
Ang III (3.5, 7, and 14 nmol/kg per minute) was infused cumulatively into the renal interstitialspace of the left (experimental) kidney each rat after a 1-hour control infusion
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18677709
Human prostate cancer cell (DU145 and LNCaP) were used for activity evaluation. LNCaP and DU145 cells were seeded onto 24-well plates at a density of 2–5x10^4 cells/well. Cells were treated with Ang-III at various concentrations as indicated in the figures for 5 days. Simultaneously, the cells were pretreated with olmesartan for 30 min, and cultured in phenol red-freeRPMI plus 0.1% BSA in the presence of Ang-III for 5 days. After incubation in 5% CO2 at 37C, cells were harvested with trypsin and cell numbers were determined with a cell counter on day 5.
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
72941629
Created by
admin on Mon Mar 31 22:41:09 GMT 2025 , Edited by admin on Mon Mar 31 22:41:09 GMT 2025
|
PRIMARY | |||
|
1354552-78-5
Created by
admin on Mon Mar 31 22:41:09 GMT 2025 , Edited by admin on Mon Mar 31 22:41:09 GMT 2025
|
NON-SPECIFIC STOICHIOMETRY | |||
|
2AY78S427U
Created by
admin on Mon Mar 31 22:41:09 GMT 2025 , Edited by admin on Mon Mar 31 22:41:09 GMT 2025
|
PRIMARY | |||
|
100900-06-9
Created by
admin on Mon Mar 31 22:41:09 GMT 2025 , Edited by admin on Mon Mar 31 22:41:09 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD